Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio A Emini

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
The Pediatric Infectious Disease Journal|April 16, 2013
Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United StatesTerry Payton, Douglas Girgenti, Robert W Frenck, et al.
The Pediatric Infectious Disease Journal|October 11, 2011
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Sylvia H Yeh, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Vaccine|January 12, 2013
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trialSven Arne Silfverdal, Carl-Erik Flodmark, Lars Rombo, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1Ronald M Kim, Elizabeth A Rouse, Kevin T Chapman, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in CanadaOtto G Vanderkooi, David W Scheifele, Douglas Girgenti, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
The Pediatric Infectious Disease Journal|April 16, 2013
Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United StatesTerry Payton, Douglas Girgenti, Robert W Frenck, et al.
The Pediatric Infectious Disease Journal|October 11, 2011
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Sylvia H Yeh, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Vaccine|January 12, 2013
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trialSven Arne Silfverdal, Carl-Erik Flodmark, Lars Rombo, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1Ronald M Kim, Elizabeth A Rouse, Kevin T Chapman, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in CanadaOtto G Vanderkooi, David W Scheifele, Douglas Girgenti, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Pageof 9